CN108430995A - 新型化合物 - Google Patents

新型化合物 Download PDF

Info

Publication number
CN108430995A
CN108430995A CN201680074553.9A CN201680074553A CN108430995A CN 108430995 A CN108430995 A CN 108430995A CN 201680074553 A CN201680074553 A CN 201680074553A CN 108430995 A CN108430995 A CN 108430995A
Authority
CN
China
Prior art keywords
compound
alkyl
disorders
pain
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680074553.9A
Other languages
English (en)
Chinese (zh)
Inventor
G·澳瓦罗
A·马拉斯科
A·德克尔
D·汉普瑞奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otif Ni Therapeutics Ltd
Original Assignee
Otif Ni Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otif Ni Therapeutics Ltd filed Critical Otif Ni Therapeutics Ltd
Publication of CN108430995A publication Critical patent/CN108430995A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680074553.9A 2015-12-16 2016-12-16 新型化合物 Pending CN108430995A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522179.9A GB201522179D0 (en) 2015-12-16 2015-12-16 Novel compounds
GB1522179.9 2015-12-16
PCT/GB2016/053958 WO2017103604A1 (en) 2015-12-16 2016-12-16 Hydantoin modulators of kv3 channels

Publications (1)

Publication Number Publication Date
CN108430995A true CN108430995A (zh) 2018-08-21

Family

ID=55274838

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680074553.9A Pending CN108430995A (zh) 2015-12-16 2016-12-16 新型化合物

Country Status (7)

Country Link
US (1) US20200377485A1 (https=)
EP (1) EP3390394B1 (https=)
JP (1) JP7036725B2 (https=)
CN (1) CN108430995A (https=)
BR (1) BR112018012177A2 (https=)
GB (1) GB201522179D0 (https=)
WO (1) WO2017103604A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066424A (zh) * 2020-02-06 2022-09-16 奥蒂福尼疗法有限公司 Kv3调节剂

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
EP3555073A1 (en) 2016-12-16 2019-10-23 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
KR102854594B1 (ko) 2018-10-16 2025-09-02 오티포니 세라피틱스 리미티드 신규한 화합물
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
AR116898A1 (es) 2018-10-30 2021-06-23 H Lundbeck As DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3
JP2022529663A (ja) 2019-04-26 2022-06-23 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ３カリウムチャネル活性化薬としてのアリールスルホニルチオフェンカルボキサミド及びアリールスルホニルフランカルボキサミド
WO2020216920A1 (en) 2019-04-26 2020-10-29 H. Lundbeck A/S N-((heteroaryl)methyl)-1-tosyl-1h-pyrazole-3-carboxamide derivatives as kv3 potassium channel activators for treating neurological and psychiatric disorders
EP3901152A1 (en) * 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
KR20240046748A (ko) * 2021-08-10 2024-04-09 오티포니 세라피틱스 리미티드 칼륨 채널 조절제
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130030012A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Compounds
CN103328467A (zh) * 2010-12-06 2013-09-25 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
WO2013175211A1 (en) * 2012-05-22 2013-11-28 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
WO2013182581A1 (en) * 2012-06-06 2013-12-12 Evonik Oil Additives Gmbh Fuel efficient lubricating oils
WO2015031036A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299383A (ja) * 1985-10-28 1987-05-08 Tokuyama Soda Co Ltd エ−テル化合物の製造方法
EP1534276B1 (en) 2002-09-05 2008-11-05 Medivir AB Non-nucleoside reverse transcriptase inhibitors
US20050080100A1 (en) 2003-10-09 2005-04-14 Pfizer Inc Pyridylamino compounds and methods of use thereof
EP1845087A1 (en) 2006-04-14 2007-10-17 Mutabilis SA Hydroxyphenyl derivatives and biological applications thereof
DK2563776T3 (en) 2010-04-27 2016-09-19 Calcimedica Inc Relations that modulate intracellular calcium
US20120316182A1 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328467A (zh) * 2010-12-06 2013-09-25 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
US20130030012A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Compounds
WO2013175211A1 (en) * 2012-05-22 2013-11-28 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
WO2013182581A1 (en) * 2012-06-06 2013-12-12 Evonik Oil Additives Gmbh Fuel efficient lubricating oils
WO2015031036A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066424A (zh) * 2020-02-06 2022-09-16 奥蒂福尼疗法有限公司 Kv3调节剂

Also Published As

Publication number Publication date
EP3390394B1 (en) 2022-05-25
BR112018012177A2 (pt) 2018-11-27
GB201522179D0 (en) 2016-01-27
JP7036725B2 (ja) 2022-03-15
US20200377485A1 (en) 2020-12-03
WO2017103604A1 (en) 2017-06-22
EP3390394A1 (en) 2018-10-24
JP2019502696A (ja) 2019-01-31

Similar Documents

Publication Publication Date Title
CN108430995A (zh) 新型化合物
CN103596943B (zh) 用作kv3抑制剂的乙内酰脲衍生物
EP3490977B1 (en) Cyclobutane derivatives as modulators of voltage-gated potassium channels
CN103974944B (zh) 用作kv3抑制剂的乙内酰脲衍生物
CN104334547A (zh) 作为kv3抑制剂的三唑类
WO2018109484A1 (en) Hydantoin modulators of kv3 channels
TWI827706B (zh) 新穎化合物
JP2013527170A (ja) 新規免疫調節剤および抗炎症化合物
Aiello et al. Design and synthesis of new transient receptor potential vanilloid type-1 (TRPV1) channel modulators: Identification, molecular modeling analysis, and pharmacological characterization of the N-(4-hydroxy-3-methoxybenzyl)-4-(thiophen-2-yl) butanamide, a small molecule endowed with agonist TRPV1 activity and protective effects against oxidative stress
CN117751119A (zh) 钾通道调节剂
JP7522203B2 (ja) Ｋｖ３モジュレーター
RU2830279C2 (ru) Новые соединения
HK40081003A (en) Kv3 modulators
HK40108089A (zh) 钾通道调节剂
HK40081003B (zh) Kv3调节剂
HK40059039A (en) Novel compounds
EA049235B1 (ru) Модуляторы kv3
BR112014013400B1 (pt) Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil
HK1203072B (en) Hydantoin derivatives useful as kv3 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180821